<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01968681</url>
  </required_header>
  <id_info>
    <org_study_id>H-4-2013-066</org_study_id>
    <nct_id>NCT01968681</nct_id>
  </id_info>
  <brief_title>Treatment of Nevus Flammeus With Alexandrite Laser</brief_title>
  <official_title>Treatment of Nevus Flammeus With Alexandrite Laser</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bispebjerg Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bispebjerg Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Nevus flammeus is a congenital vascular malformation. Nevus flammeus is traditionally treated
      with pulsed dye lasers (PDL); however, around 20 percent of patients are poor responders and
      do not get satisfactory results from pulsed dye laser treatments.

      Small studies with alexandrite lasers indicate that this may be an alternative treatment for
      individuals with nevus flammeus. This study assesses the clinical effect and side effects of
      alexandrite laser treatment for nevus flammeus using different treatment settings.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction in clinical appearance on a 10-point scale</measure>
    <time_frame>6-8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Skin reflectance measurement to assess degree of redness</measure>
    <time_frame>6-8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Skin reflectance to assess degree of pigmentation</measure>
    <time_frame>6-8 weeks</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Clinical assessment of pigmentation</measure>
    <time_frame>6-8 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Clinical assessment of scar tissue formation</measure>
    <time_frame>6-8 weeks</time_frame>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Nevus Flammeus</condition>
  <arm_group>
    <arm_group_label>Alexandrite laser treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Alexandrite laser</intervention_name>
    <description>3 different alexandrite laser settings are used in respectively 3 different treatment areas and compared with a non-treated control area.</description>
    <arm_group_label>Alexandrite laser treatment</arm_group_label>
    <other_name>Candela Gentle Max</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  10 or more years of age

          -  Fitzpatrick Skin Type I-III

          -  Previously untreated or pulsed dye laser-insufficiently treated nevus flammeus

          -  Nevus flammeus size minimum 8 x 2 centimeter within one anatomical region

          -  Written and oral informed consent

        Exclusion Criteria:

          -  Known light sensibility toward visible light

          -  Tendency to develop hypertrophic scars or keloids

          -  Fitzpatrick Skin Type IV-VI

          -  Individuals, that are obviously pigmented due to recent sun exposure or sun beds

          -  Treatment with systemic retinoids within 6 months

          -  Pregnancy and lactation

          -  Unwillingness to complete protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Merete Haedersdal, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bispebjerg Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bispebjerg Hospital</name>
      <address>
        <city>Copenhagen</city>
        <zip>2400</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <removed_countries>
    <country>Belgium</country>
  </removed_countries>
  <verification_date>February 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 21, 2013</study_first_submitted>
  <study_first_submitted_qc>October 21, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 24, 2013</study_first_posted>
  <last_update_submitted>February 22, 2015</last_update_submitted>
  <last_update_submitted_qc>February 22, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 24, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Bispebjerg Hospital</investigator_affiliation>
    <investigator_full_name>Merete Haedersdal</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nevus</mesh_term>
    <mesh_term>Port-Wine Stain</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

